Guardant Health, Inc.
Extracted from this filing and checked against the source text.
Guardant Health, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.
Proposal 2 in the Proxy Statement, a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, was approved by the following vote: Votes For Votes Against Abstentions 84,048,978 26,878 32,392View on SEC.gov
Guardant Health, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-14 meeting.
Proposal 3 in the Proxy Statement, a proposal to approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 66,909,185 10,481,515 178,806 6,538,742View on SEC.gov
Guardant Health, Inc. shareholders approved Election of Directors at the 2023-06-14 meeting.
All of the nominees for director listed in Proposal 1 in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 27, 2023 (the “ Proxy Statement ”), were elected to serve on the Company’s board of directors by the following vote: Name of Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 48,391,638 29,177,868 6,538,742 Meghan Joyce 57,913,641 19,655,865 6,538,742 Samir Kaul 76,695,081 874,425 6,538,742View on SEC.gov
63 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.